Regeneron Pharmaceuticals Inc (REGN)
963.50
-3.40
(-0.35%)
USD |
NASDAQ |
Mar 28, 12:31
Regeneron Pharmaceuticals Enterprise Value: 97.27B for March 27, 2024
Enterprise Value Chart
Historical Enterprise Value Data
Date | Value |
---|---|
March 27, 2024 | 97.27B |
March 26, 2024 | 96.90B |
March 25, 2024 | 96.63B |
March 22, 2024 | 97.30B |
March 21, 2024 | 97.39B |
March 20, 2024 | 97.27B |
March 19, 2024 | 96.91B |
March 18, 2024 | 96.50B |
March 15, 2024 | 97.00B |
March 14, 2024 | 96.40B |
March 13, 2024 | 97.11B |
March 12, 2024 | 97.67B |
March 11, 2024 | 97.00B |
March 08, 2024 | 97.48B |
March 07, 2024 | 97.97B |
March 06, 2024 | 97.84B |
March 05, 2024 | 97.08B |
March 04, 2024 | 97.74B |
March 01, 2024 | 99.01B |
February 29, 2024 | 97.18B |
February 28, 2024 | 99.54B |
February 27, 2024 | 100.17B |
February 26, 2024 | 99.72B |
February 23, 2024 | 98.84B |
February 22, 2024 | 97.05B |
Date | Value |
---|---|
February 21, 2024 | 95.72B |
February 20, 2024 | 95.07B |
February 16, 2024 | 95.20B |
February 15, 2024 | 95.93B |
February 14, 2024 | 95.17B |
February 13, 2024 | 94.37B |
February 12, 2024 | 95.09B |
February 09, 2024 | 95.79B |
February 08, 2024 | 95.02B |
February 07, 2024 | 94.15B |
February 06, 2024 | 94.07B |
February 05, 2024 | 93.91B |
February 02, 2024 | 94.88B |
February 01, 2024 | 96.27B |
January 31, 2024 | 94.62B |
January 30, 2024 | 96.48B |
January 29, 2024 | 96.05B |
January 26, 2024 | 94.32B |
January 25, 2024 | 95.29B |
January 24, 2024 | 94.89B |
January 23, 2024 | 95.59B |
January 22, 2024 | 94.30B |
January 19, 2024 | 93.27B |
January 18, 2024 | 92.90B |
January 17, 2024 | 92.80B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
27.20B
Minimum
Oct 02 2019
100.17B
Maximum
Feb 27 2024
61.14B
Average
62.25B
Median
Enterprise Value Benchmarks
Vertex Pharmaceuticals Inc | 96.63B |
Eli Lilly and Co | 762.26B |
Pfizer Inc | 215.30B |
AbbVie Inc | 365.19B |
Puma Biotechnology Inc | 273.20M |
Enterprise Value Related Metrics
Net Income (Quarterly) | 1.160B |
Revenue (Quarterly) | 3.434B |
Total Expenses (Quarterly) | 2.431B |
EPS Diluted (Quarterly) | 10.19 |
Gross Profit Margin (Quarterly) | 84.95% |
Profit Margin (Quarterly) | 33.77% |
Earnings Yield | 3.61% |
Operating Earnings Yield | 3.86% |
Normalized Earnings Yield | 3.979 |